Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03, FiscalAI reports. The business had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $4.14 million. Lexicon Pharmaceuticals had a negative net margin of 161.80% and a negative return on equity of 35.88%.
Here are the key takeaways from Lexicon Pharmaceuticals’ conference call:
- SONATA-HCM enrollment is complete, with 542 patients enrolled, including 440 with non-obstructive HCM. Top-line results are expected in Q1 2027; efficacy remains unproven pending the readout.
- Lexicon now expects to resubmit the ZYNQUISTA NDA in type 1 diabetes in Q1 2027, later than initially anticipated, as it prepares the investigator-led STENO1 dataset to regulatory standards. The company said STENO1’s DKA rate was about one event per 100 patient-years and comparable to standard of care, but FDA review and approval remain uncertain.
- Early preclinical studies showed pilavapadin reduced body weight by 14% alone and 31% combined with semaglutide, versus 25% with semaglutide alone. The obesity opportunity is preliminary, and the company said further studies are needed.
- Third-quarter revenue fell to $11.3 million from $14.2 million a year earlier, while net loss widened to $14.0 million from $12.8 million. Cash, cash equivalents and short-term investments were $183.2 million at quarter-end, and 2026 operating expense guidance was maintained at $100 million to $110 million.
- Novo Nordisk’s LX9851 phase I program is progressing, and Lexicon received its third $10 million milestone payment from Novo this year. Additional milestone payments may be possible as development advances.
Lexicon Pharmaceuticals Price Performance
Lexicon Pharmaceuticals stock traded up $0.17 during midday trading on Friday, reaching $1.78. 3,598,478 shares of the stock were exchanged, compared to its average volume of 1,937,201. The company’s fifty day moving average is $1.81 and its 200-day moving average is $1.89. The company has a debt-to-equity ratio of 0.29, a quick ratio of 13.29 and a current ratio of 13.37. The firm has a market cap of $792.03 million, a PE ratio of -12.71 and a beta of 1.10. Lexicon Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $2.68.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on LXRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 21st. Zacks Research lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 3rd. Wall Street Zen cut Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, October 31st. Finally, Cantor Fitzgerald began coverage on Lexicon Pharmaceuticals in a report on Monday, September 28th. They set an “overweight” rating and a $8.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.70.
Check Out Our Latest Stock Analysis on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals News Roundup
Here are the key news stories impacting Lexicon Pharmaceuticals this week:
- Positive Sentiment: Lexicon posted a Q3 loss of $0.03 per share, narrower than the $0.06 loss analysts expected and the $0.04 loss a year earlier. Revenue of $11.25 million also topped estimates of about $4.14 million. Zacks earnings report
- Positive Sentiment: The Phase 3 SONATA-HCM trial is substantially overenrolled, with top-line results expected in Q1 2027. This could provide a significant upcoming clinical catalyst. Lexicon clinical and financial update
- Positive Sentiment: Lexicon said positive STENO1 safety data strengthen the benefit-risk profile for a ZYNQUISTA NDA resubmission, potentially advancing another path to value creation. Lexicon clinical and financial update
- Neutral Sentiment: Phase 1 clinical development of LX9851 is ongoing at Novo Nordisk; the update indicates continued progress but offered no new results or specific timeline. Lexicon clinical and financial update
- Negative Sentiment: Despite beating estimates, Lexicon still reported a quarterly loss, reflecting continued profitability risk as investors await clinical and regulatory progress.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.
Lexicon’s commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.
See Also
- Five stocks we like better than Lexicon Pharmaceuticals
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
